Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $75.33 USD
Change Today -0.82 / -1.08%
Volume 1.6M
DGX On Other Exchanges
Symbol
Exchange
Stuttgart
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

quest diagnostics inc (DGX) Snapshot

Open
$75.46
Previous Close
$76.15
Day High
$75.89
Day Low
$74.87
52 Week High
03/24/15 - $78.33
52 Week Low
04/28/14 - $54.90
Market Cap
10.8B
Average Volume 10 Days
1.5M
EPS TTM
$4.06
Shares Outstanding
143.8M
EX-Date
04/6/15
P/E TM
18.6x
Dividend
$1.52
Dividend Yield
1.82%
Current Stock Chart for QUEST DIAGNOSTICS INC (DGX)

quest diagnostics inc (DGX) Related Businessweek News

View More BusinessWeek News

quest diagnostics inc (DGX) Details

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; analytic, on-site prevention, and wellness services; and risk assessment services for the life insurance industry. It also develops, manufactures, and markets diagnostic products, including Simplexa molecular chemistries for testing infectious disease and hospital-acquired infections; HerpeSelect HSV serology; and DxSelect IFA and ELISA products for testing infectious diseases. In addition, the company offers molecular diagnostic products in various segments, such as HIV-1 drug resistance testing under the ViroSeq brand name; and reproductive genetics and transplantation under the Atria and AlleleSeqr brand names. Further, it provides Care360 EHR, a solution that allows doctors to electronically create, manage, and distribute patient encounter notes, as well as for patient communication through a patient portal; and ChartMaxx, an enterprise content management system for hospitals. The company primarily offers its diagnostic information services under the Quest Diagnostics, AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Solstas, and Summit Health brands to patients, physicians, hospitals, accountable care organizations, integrated delivery networks, health plans, employers, and other customers through a network of laboratories, patient service centers, and phlebotomists in physician offices. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.

45,000 Employees
Last Reported Date: 02/24/15
Founded in 1967

quest diagnostics inc (DGX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $550.0K
Senior Vice President of Operations
Total Annual Compensation: $536.5K
Chief Medical Officer, Senior Vice President ...
Total Annual Compensation: $573.9K
Senior Vice President and Group Executive of ...
Total Annual Compensation: $534.6K
Compensation as of Fiscal Year 2014.

quest diagnostics inc (DGX) Key Developments

Quest Diagnostics Inc. Unveils Suite of New Technology Solutions

Quest Diagnostics will unveil a suite of new technology solutions during the HIMSS 2015 Annual Conference & Exhibition. The new solutions, featuring Interactive Insights by Care360 reports and IntelliTest Analytics, are designed to promote clinically appropriate test selection and tracking of quality and care metrics, among other benefits, to enhance patient care and outcomes for both the individual patient and large managed populations.

Quest Diagnostics Inc., Quintiles Transnational Holdings Inc. - Special Call

To discuss definitive agreement between Quintiles and Quest Diagnostics to form a global clinical trials laboratory services business

Quintiles and Quest Diagnostics to Form Joint Venture to Provide Global Clinical Trials Laboratory Services

Quintiles and Quest Diagnostics announced a definitive agreement to form a global clinical trials laboratory services business. By combining the clinical trials laboratory operations of two industry leaders, the new entity will provide customers with the depth of capabilities and end-to-end clinical trial laboratory services required to succeed in the increasingly complex biopharmaceutical industry. The new entity will offer a compelling value proposition to solidify its position as the second-largest central laboratory services company in the world. The joint venture would have generated approximately $575 million in revenues in 2014, and will offer a superior breadth of services and test menu to its customers across all segments of the biopharmaceutical industry – a group that includes all of the top-20 large biopharmaceutical companies. Upon closing of the transaction, Quintiles will own 60% and Quest Diagnostics will own 40% of the new joint venture. Quintiles’ scale, clinical trial expertise, and diverse therapeutic experience coupled with Quest Diagnostics’ operational, scientific and quality excellence, supply chain network and informatics promise greater innovation, quality and value for biopharmaceutical customers. In addition, customers will benefit from a globally scaled and agile business model that is singularly focused on delivering top-quality laboratory services informed by deep medical and clinical knowledge. Clinical, scientific and statistical excellence is becoming increasingly important for successful laboratory work as part of the regulatory approval process. To meet these needs, the entity will draw upon the deep scientific, medical and data expertise of Quintiles and Quest Diagnostics, which together have a team of approximately 3,500 medical doctors, Ph.D.s and biostatisticians as well as cutting-edge experience, expertise and capabilities in the areas of genomics and precision medicine. The new entity also will leverage a number of additional resources from the broader Quintiles and Quest Diagnostics organizations, including the Infosario® technology platform and Quest Diagnostics’ robust data analytics capabilities. Both companies are bioinformatics leaders in their respective fields – positions that have been built upon and honed from diverse experience and data access. Quest Diagnostics draws from 20 billion test results, and Quintiles’ assets include electronic health records representing more than 60 million patient lives and a network of 250,000 clinical investigators. The joint venture will be led by an experienced global management team appointed from Quintiles and Quest Diagnostics. Built upon the strong histories and foundations of quality delivery of its parent organizations, the new entity will provide customers with a variety of advanced testing capabilities and services. These will enable end-to-end companion diagnostic development with regulatory, reimbursement and commercial strategies, to help biopharmaceutical customers’ precision medicine efforts. It also will help enhance quality and efficiency by leveraging Quest Diagnostics’ supply chain that serves approximately half of the physicians and hospitals in the U.S. and includes 2,200 service centers, 3,000 couriers and connectivity solutions used by 250,000 healthcare providers.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $75.33 USD -0.82

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMerieux €92.00 EUR -1.05
Hologic Inc $32.47 USD -0.355
Laboratory Corp of America Holdings $124.41 USD -1.08
QIAGEN NV €23.06 EUR -0.57
Roper Industries Inc $167.08 USD -3.57
View Industry Companies
 

Industry Analysis

DGX

Industry Average

Valuation DGX Industry Range
Price/Earnings 19.9x
Price/Sales 1.5x
Price/Book 2.5x
Price/Cash Flow 16.7x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST DIAGNOSTICS INC, please visit www.questdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.